R5 Variants of Human Immunodeficiency Virus Type 1 Preferentially Infect CD62L − CD4 + T Cells and Are Potentially Resistant to Nucleoside Reverse Transcriptase Inhibitors

Abstract

ABSTRACT The persistence of human immunodeficiency virus type 1 (HIV-1) in memory CD4 + T cells is a major obstacle to the eradication of the virus with current antiretroviral therapy. Here, we investigated the effect of the activation status of CD4 + T cells on the predominance of R5 and X4 HIV-1 variants in different subsets of CD4 + T cells in ex vivo-infected human lymphoid tissues and peripheral blood mononuclear cells (PBMCs). In these cell systems, we examined the sensitivity of HIV replication to reverse transcriptase inhibitors. We demonstrate that R5 HIV-1 variants preferentially produced productive infection in HLA-DR − CD62L − CD4 + T cells. These cells were mostly in the G 1 b phase of the cell cycle, divided slowly, and expressed high levels of CCR5. In contrast, X4 HIV-1 variants preferentially produced productive infection in activated HLA-DR + CD62L + CD4 + T cells, which expressed high levels of CXCR4. The abilities of the nucleoside reverse transcriptase inhibitors (NRTI) zidovudine and lamivudine to stop HIV-1 replication were 20 times greater in activated T cells than in slowly dividing HLA-DR − CD62L − CD4 + T cells. This result, demonstrated both in a highly physiologically relevant ex vivo lymphoid tissue model and in PBMCs, correlated with higher levels of thymidine kinase mRNA in activated than in slowly dividing HLA-DR − CD62L − CD4 + T cells. The non-NRTI nevirapine was equally efficient in both cell subsets. The lymphoid tissue and PBMC-derived cell systems represent well-defined models which could be used as new tools for the study of the mechanism of resistance to HIV-1 inhibitors in HLA-DR − CD62L − CD4 + T cells.